Product Code: GERPH606
GervanoRA's pipeline analysis and opportunity assessment report "Myasthenia Gravis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, H2 2019" analyzed and assessed Myasthenia Gravis pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Myasthenia Gravis industry.
The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Myasthenia Gravis area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Myasthenia Gravis industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Drug Class, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Stage of development, Pipeline Analytics by Target and Pipeline Analytics by Companies.
Our comprehensive analysis on the Myasthenia Gravis drug pipeline identified a total of 29 drug candidates undergoing different stages of development- from Early R&D to Phase 3 stage. Among these, seven molecules are in the Phase 3 stage of development, seven molecules are in Phase 2, two molecules are in Phase 1 and a total of 13 molecules are in non clinical stage of development. We have also identified six drug molecules which have been discontinued or terminated due to various reasons from further development for Myasthenia Gravis.
The report has covered more than 25 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 14 Emerging companies in the domain and hence deriving the key leader.
Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:
- Unmet needs and Opportunities
- Epidemiology and Epidemiology forecast till 2025
- Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
- Patent Analytics of Pipeline Molecules
- Pipeline Analysis and Estimated Pipeline Drug Approval Time lines of all Clinical Stage Pipeline Drug Candidates
- Current and Future Competitive Landscape
- Key Established Company Profiles with SWOT Analysis
- Emerging Company Profiles with Opportunity Assessments
Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.
TABLE OF CONTENTS
1. INTRODUCTION
- 1.1. REPORT DESCRIPTION
- 1.2. METHODOLOGY
- 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
- 1.4. ABOUT US: GERVANORA DATA SERVICES
2. EXECUTIVE SUMMARY
- 2.1. REPORT SUMMARY
- 2.2 KEY EVENTS IN THE MYASTHENIA GRAVIS COMPETITIVE SPACE
- 2.3. REPORT MAJOR FINDINGS
- 2.3.1. DRIVERS
- 2.3.2. RESTRAINTS
- 2.3.3. OPPORTUNITIES
3. MYASTHENIA GRAVIS DISEASE OVERVIEW
- 3.1. DISEASE DEFINITION AND SYMPTOMS
- 3.2. DISEASE CAUSE AND CLASSIFICATION
- 3.3. DISEASE DIAGNOSIS
- 3.4. TREATMENT ALGORITHM AND GUIDELINES
- 3.5. EPIDEMIOLOGY STUDIES
- 3.5.1. GLOBAL AND HISTORICAL TRENDS
- 3.6. EPIDEMIOLOGY FORECAST
- 3.6.1. FORECAST METHODOLOGY AND ASSUMPTIONS
- 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
4. MARKET DYNAMICS OF MYASTHENIA GRAVIS DISEASE COMPETITIVE SPACE
- 4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
- 4.1.1 MERGERS AND ACQUISITIONS
- 4.1.2 COLLABORATION AGREEMENTS
- 4.1.3 LICENSING AGREEMENTS
- 4.1.4 FINANCING DEALS
- 4.2. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
- 4.2.1. PATENT ANALYTICS OF PIPELINE DRUGS
5. PIPELINE DRUGS ANALYTICS OF MYASTHENIA GRAVIS DISEASE
- 5.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
- 5.1.1. PHASE 3 PIPELINE DRUGS
- 5.1.2. PHASE 2 PIPELINE DRUGS
- 5.1.3. PHASE 1 PIPELINE DRUGS
- 5.1.4. PRECLINICAL PIPELINE DRUGS
- 5.1.5. EARLY R&D PIPELINE DRUGS
- 5.1.6. WITHDRAWN AND TERMINATED PIPELINE DRUGS
- 5.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY
- 5.2.1. UNMET NEEDS AND OPPORTUNITIES
- 5.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION
- 5.3.1. UNMET NEEDS AND OPPORTUNITIES
- 5.4. PIPELINE DRUGS ANALYTICS BY DRUG CLASS
- 5.4.1. UNMET NEEDS AND OPPORTUNITIES
- 5.5. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION
- 5.5.1. UNMET NEEDS AND OPPORTUNITIES
- 5.6. PIPELINE DRUGS ANALYTICS BY TARGET
- 5.7. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE
- 5.8. PIPELINE DRUGS ANALYTICS BY UNIVERSITIES AND INSTITUTES - LICENSING OPPORTUNITIES
6. CLINICAL STAGE PIPELINE DRUG DESCRIPTIONS AND DEVELOPMENT MILESTONES
- 6.1. PHASE 3 PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
- ALEXION PHARMACEUTICALS INC - SOLIRIS (ECULIZUMAB)
- ALEXION PHARMACEUTICALS INC - ULTOMIRIS
- ARGENX SE - EFGARTIGIMOD (ARGX-113)
- CATALYST PHARMA - FIRDAPSE (AMIFAMPRIDINE PHOSPHATE)
- UCB SA - ROZANOLIXIZUMAB/UCB7665
- RA PHARMACEUTICALS INC - ZILUCOPLAN
- 6.2. PHASE 2 PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
- IMMUNOVANT - IMVT-1401
- DAS THERAPEUTICS - GTB-004/DAS-MG
- MOMENTA PHARMACEUTICALS INC - NIPOCALIMAB (M281)
- CARTESIAN THERAPEUTICS - DESCARTES-08
- ALEXION PHARMACEUTICALS INC - ALXN 1830
- 6.3. PHASE 1 PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
- ALPHA CANCER TECHNOLOGIES INC - ACT-101 (AFP)
- KASHIV BIOSCIENCES LLC/AMNEAL PHARMACEUTICALS - K127 (PYRIDOSTIGMINE)
7. ESTIMATED APPROVAL TIMELINES OF MYASTHENIA GRAVIS PIPELINE DRUGS
- 7.1. METHODOLOGY
- 7.2. ESTIMATED APPROVAL TIMELINES US & EX-US
8. OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING
- 8.1. EXTERNAL DEPENDENCIES
- 8.2. PIPELINE PORTFOLIO
- 8.3. EXPECTED MARKET ENTRIES
- 8.4. PATENTS AND EXCLUSIVITY
- 8.5. MARKET DYNAMICS WITH PARTNERING ACTIVITIES
- 8.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES
- 8.7. COMPANY DEVELOPMENTS
9. ASSESSMENT OF CURRENT AND FUTURE COMPETITIVE LANDSCAPE THROUGH COMPANY PROFILES
- 9.1. ESTABLISHED COMPANIES
- 9.1.1. KEY COMPANY PROFILES AND SWOT ANALYSIS
- 9.1.1.1. ALEXION PHARMACEUTICALS INC
- 9.1.1.2. UCB SA
- 9.1.1.3. TAKEDA PHARMACEUTICAL COMPANY LIMITED
- 9.1.1.4. NOVARTIS AG
- 9.1.1.5. CATALYST PHARMACEUTICALS INC
- 9.2. EMERGING COMPANIES
- 9.2.1. KEY EMERGING COMPANY PROFILES WITH COMPETITIVE OPPORTUNITY ASSESSMENTS
- 9.2.1.1 ARGENX SE
- 9.2.1.2. ALPHA CANCER TECHNOLOGIES INC
- 9.2.1.3. MOMENTA PHARMACEUTICALS INC
- 9.2.1.4. RA PHARMACEUTICALS INC
- 9.2.1.5. VIELA BIO, INC.
- 9.2.1.6. GT BIOPHARMA
- 9.2.1.7. IMMUNOVANT, INC
- 9.2.1.8. KASHIV BIOSCIENCES LLC
- 9.2.1.9. CARTESIAN THERAPEUTICS, INC
- 9.2.1.10. AKARI THERAPEUTICS PLC
- 9.2.1.11. CABALETTA BIO INC
- 9.2.1.12. NEUROTUNE AG
- 9.2.1.13. TOLERANZIA AB
- 9.2.1.14. AHEAD THERAPEUTICS S.L
10. ABBREVIATIONS